LeonaBio, Inc. Payments to Acquire Debt Securities, Available-for-sale
LeonaBio, Inc. (LONA) reported Payments to Acquire Debt Securities, Available-for-sale of $30.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-14
- LeonaBio, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $10.22M, a 68.51% increase year-over-year.
- LeonaBio, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $20.61M, a 102.09% increase year-over-year.
- LeonaBio, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $18.04M, a 541.47% increase year-over-year.
- LeonaBio, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $3.34M.
- LeonaBio, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $37.64M, a 166.33% increase from fiscal 2024.
- LeonaBio, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $14.13M, a 48.92% decline from fiscal 2023.
- LeonaBio, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $27.67M, a 70.96% decline from fiscal 2022.
- LeonaBio, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $95.29M, a 68.15% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $30.84M 10-Q · filed 2026-08-14 | $48.88M derived: sum of 3 quarters · filed 2026-08-14 | $52.21M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $20.61M 10-Q · filed 2026-05-07 | $38.65M derived: sum of 2 quarters · filed 2026-05-07 | $41.99M derived: sum of 3 quarters · filed 2026-05-07 | $48.06M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $18.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $21.37M derived: sum of 2 quarters · filed 2026-03-31 | $27.44M derived: sum of 3 quarters · filed 2026-08-14 | $37.64M 10-K · filed 2026-03-31 |
| 2025-09-30 | $3.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $9.40M derived: sum of 2 quarters · filed 2026-08-14 | $19.61M 10-Q · filed 2025-11-06 | $22.42M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $6.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $16.27M 10-Q · filed 2026-08-14 | $19.08M derived: sum of 3 quarters · filed 2026-08-14 | $19.08M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $10.20M 10-Q · filed 2026-05-07 | $13.01M derived: sum of 2 quarters · filed 2026-05-07 | $13.01M derived: sum of 3 quarters · filed 2026-05-07 | $18.42M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.81M derived: sum of 2 quarters · filed 2026-03-31 | $8.22M derived: sum of 3 quarters · filed 2026-03-31 | $14.13M 10-K · filed 2026-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.41M derived: sum of 2 quarters · filed 2025-11-06 | $11.32M 10-Q · filed 2025-11-06 | $11.32M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $5.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $11.32M 10-Q · filed 2025-08-07 | $11.32M derived: sum of 3 quarters · filed 2025-08-07 | $14.10M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $5.91M 10-Q · filed 2025-05-09 | $5.91M derived: sum of 2 quarters · filed 2025-05-09 | $8.69M derived: sum of 3 quarters · filed 2025-05-09 | $23.87M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.78M derived: sum of 2 quarters · filed 2025-02-27 | $17.96M derived: sum of 3 quarters · filed 2025-02-27 | $27.67M 10-K · filed 2025-02-27 |
| 2023-09-30 | $2.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $17.96M derived: sum of 2 quarters · filed 2024-11-07 | $27.67M 10-Q · filed 2024-11-07 | $37.84M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $15.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $24.89M 10-Q · filed 2024-08-01 | $35.06M derived: sum of 3 quarters · filed 2024-08-01 | $68.51M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $9.71M 10-Q · filed 2024-05-15 | $19.88M derived: sum of 2 quarters · filed 2024-05-15 | $53.33M derived: sum of 3 quarters · filed 2024-05-15 | $87.17M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $10.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $43.62M derived: sum of 2 quarters · filed 2024-02-22 | $77.46M derived: sum of 3 quarters · filed 2024-02-22 | $95.29M 10-K · filed 2024-02-22 |
| 2022-09-30 | $33.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $67.29M derived: sum of 2 quarters · filed 2023-11-09 | $85.12M 10-Q · filed 2023-11-09 | $114.94M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $33.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $51.67M 10-Q · filed 2023-08-10 | $81.49M derived: sum of 3 quarters · filed 2023-08-10 | $177.30M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $17.83M 10-Q · filed 2023-05-11 | $47.65M derived: sum of 2 quarters · filed 2023-05-11 | $143.46M derived: sum of 3 quarters · filed 2023-05-11 | $223.88M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $29.82M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $125.63M derived: sum of 2 quarters · filed 2023-03-23 | $206.05M derived: sum of 3 quarters · filed 2023-03-23 | $299.20M 10-K · filed 2023-03-23 |
| 2021-09-30 | $95.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $176.24M derived: sum of 2 quarters · filed 2022-11-10 | $269.38M 10-Q · filed 2022-11-10 | $401.93M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $80.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $173.56M 10-Q · filed 2022-08-15 | $306.12M derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | $93.14M 10-Q · filed 2022-05-12 | $225.70M derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $132.56M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $226.84M 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $94.28M 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $995.00K 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $995.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |